Výsledky vyhledávání

Application of organometallic catalysts for the synthesis of o-tolyl benzonitrile, a key starting material for sartans

Autor: Sharada Prasanna Swain, Anupam Jana, V. Ravichandiran

Publikováno v: New Journal of Chemistry. 45:17753-17771

Biaryl compounds are an important class of aromatic compounds used for the synthesis of antiviral, antihypertensive, and antifungal drugs. The familiar methods for the synthesis of biaryl compounds are Pd-, Ni-catalyzed couplings reactions, such as S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80621fda06b0df871e7f01f9bdb292fc
https://doi.org/10.1039/d1nj03380h

Zobrazit plný text záznamu

Angiotensin II-receptor antagonists: An overview

Autor: Raquel Dina, Mahtab Jafari

Publikováno v: American Journal of Health-System Pharmacy. 57:1231-1241

Angiotensin II (AT-II)-receptor antagonists are reviewed. Research focused on blocking the renin-angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors, which are effective in the treatment of hypertension but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77d179ff8838651debb8577a2c58bb93
https://doi.org/10.1093/ajhp/57.13.1231

Zobrazit plný text záznamu

Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study

Autor: Steven G. Chrysant, Joel M. Neutel, Michael Weber, William J. Mroczek, Dennis A. Ruff, Vardaman Buckalew

Publikováno v: American Heart Journal. 137:118-125

Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an alternative to angiotensin-converting enzyme inhibitors in the treatment of hypertension. Tasosartan is a newly developed nonpeptid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::742a6a450de0fbb622e995f9e18df2fd
https://doi.org/10.1016/s0002-8703(99)70467-9

Zobrazit plný text záznamu

Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients

Autor: J. Cléroux, Caroline Rhéaume, Yves Lacourcière, Paulo H. Waib

Publikováno v: Journal of Hypertension. 16:2085-2089

Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal exercise, (2) on exercise peak oxygen uptake, and (3) on regional haemodynamics at rest in a control condition and during the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ce02e179ee55ca4fe2e7c64f0b2bcf3
https://doi.org/10.1097/00004872-199816121-00034

Zobrazit plný text záznamu

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension

Autor: William B. Smith, Alan H. Gradman, Jacques de Champlain, James L. Pool, Laura P. Svetkey, Pierre Larochelle, Yves Lacourcière

Publikováno v: American Journal of Hypertension. 11:454-461

Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind, placebo-controlled, multicenter trial at 21 sites in the United States and Canada. After a 2-week, placebo washout qualificati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5a00a725b7fa67dea86fa50ec83d4d6a
https://doi.org/10.1016/s0895-7061(97)00487-1

Zobrazit plný text záznamu

The New Angiotensin II Receptor Antagonist, IrbesartanPharmacokinetic and Pharmacodynamic Considerations

Autor: Hans R. Brunner

Publikováno v: American Journal of Hypertension. 10:311S-317S

This article reviews the pharmacokinetics and pharmacodynamics of angiotensin II (AII) receptor antagonists (AIIRA), with particular focus on the novel compound irbesartan. Irbesartan has the highest oral bioavailability in its class (60% to 80%) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c60efc03241d5fa180e9bffb8db5c610
https://doi.org/10.1016/s0895-7061(97)00391-9

Zobrazit plný text záznamu

Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension

Autor: Alan H. Gradman, Michael A. Weber, Suzanne Oparil, Vasilios Papademetriou

Publikováno v: Current Therapeutic Research. 58:930-943

This paper summarizes tolerability data for 1420 patients with essential hypertension who were enrolled in eight double-masked, controlled clinical trials and who received tasosartan, a long-acting, nonpeptidic angiotensin II AT 1 receptor blocker. A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a98dc7812a9f05192aa33182beb4534f
https://doi.org/10.1016/s0011-393x(97)80060-4

Zobrazit plný text záznamu

ChemInform Abstract: Novel Human Metabolites of the Angiotensin-II Antagonist Tasosartan and Their Pharmacological Effects

Autor: Boyd L. Harrison, Sie Yearl Chai, Gregory S. Friedrichs, Michael Chlenov, David L. Crandall, Hassan Mahmoud Elokdah, John Primeau

Publikováno v: ChemInform. 33

Three novel metabolites of the angiotensin-II (A-II) receptor antagonist tasosartan have been identified in humans, and the syntheses and pharmacologic profiling of these metabolites are reported. Each metabolite bound the human A-II receptor with IC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::61d6feee2c40fe0d92b097591453def4
https://doi.org/10.1002/chin.200245219

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání